BBIO BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $10.1M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Kumar Neil 2 fills | Chief Executive Officer | Sell 10b5-1 | 10,000 | $69.08 | $690.8K | 496,965 −2% of holding | |
| Kumar Neil 3 fills | Chief Executive Officer | Sell 10b5-1 | 10,000 | $84.03 | $840.3K | 507,586 −1.9% of holding | |
| Kumar Neil 4 fills | Chief Executive Officer | Sell 10b5-1 | 34,980 | $82.53 | $2.9M | 276,407 −11.2% of holding | |
| Apuli Maricel | Chief Accounting Officer | Sell 10b5-1 | 2,000 | $80.06 | $160.1K | 127,401 −1.5% of holding | |
| Cook Jennifer E. 2 fills | Director | Sell 10b5-1 | 148,589 | $88.54 | $13.2M | 120,805 −55.2% of holding | |
| Ellis Andrea | Director | Sell 10b5-1 | 17,167 | $84.00 | $1.4M | 22,579 −43.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.